ClinicalTrials.gg
RecruitingNCT07531901Updated Jul 20, 2026

Evaluating the Feasibility and Reliability of Using Handheld Nebulizers to Conduct Cough Sensitivity Testing With Citric Acid

An interventional study of Cosmed QuarkSpiro Dosimeter-Controlled Nebulizer and DeVilbiss 45 Handheld Nebulizer in Cough Reflex Sensitivity, sponsored by University of Montana. Recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by University of Montana · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Cough with a site in United States — 18 open to participants now, 21 under way, none of them phase 3. Cough · United States.

Planned enrollment
77th of 86
10 · median 63
Started
2026
with 5 others
No phase
32 of 104
9 open now
Primary completion
2027-02
later than 8 of 20 live
Registered
99th of 104
by date
Lead sponsor
4 of 104
University of Montana

Among the 104 studies in Cough with a site in United States, this one is the 77th largest by planned enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2026, is one of 32 with no phase, reaches primary completion later than 8 of the 20 other live ones, and was the 99th registered.

Cough

429 studies on the registry are indexed under Cough; 68 are open to participants now.

Browse Cough studies →

Open to participants now

18 of the 104 studies in Cough with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Cough studies recruiting now, 20 (44%) set no upper age limit and 14 (31%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Cough with a site in United States, or all of them as a file.
02

Study summary

Objective cough reflex sensitivity testing is typically restricted to specialized research laboratories due to reliance on expensive dosimeter-controlled aerosol delivery systems. This study evaluates the feasibility and reliability of a low-cost alternative method using a handheld nebulizer for citric acid cough challenge testing. Healthy adult participants will complete cough reflex sensitivity testing using both a standard dosimeter-controlled nebulizer system (Cosmed QuarkSpiro) and a handheld nebulizer (DeVilbiss 45). The study will compare cough threshold outcomes between methods to determine whether handheld nebulizer-based testing produces comparable and reproducible measurements.

Read the detailed description

Cough reflex sensitivity testing is widely used in respiratory research to quantify airway sensory responsiveness. Traditional testing protocols use dosimeter-controlled nebulizer systems to deliver precise concentrations of aerosolized tussive agents such as citric acid. However, these systems are costly and require specialized laboratory infrastructure, limiting access to objective cough testing in outpatient and community-based settings.

This study investigates the feasibility and reliability of using a commercially available handheld nebulizer as a low-cost alternative for cough reflex sensitivity testing. Healthy adult volunteers will undergo standardized cough challenge testing using citric acid delivered through two aerosol delivery systems: a laboratory dosimeter-controlled nebulizer (Cosmed QuarkSpiro) and a handheld nebulizer (DeVilbiss 45). The primary outcomes will be cough threshold measures (e.g., C2 and C5), defined as the citric acid concentration that elicits two or five coughs.

Participants will complete testing sessions using both delivery methods under controlled conditions. Findings from this proof-of-concept study will inform future research aimed at expanding access to objective cough assessment in clinical and community settings.

03

Conditions studied

  • Cough Reflex Sensitivity

Browse trials for

Keywords

  • cough challenge testing
  • cough reflex sensitivity testing
04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults at least 18 years of age
  • Consent to audio/video recording of the research sessions for research purposes
  • Spirometry testing results obtained by study team on same day of first testing session with /FVC ratio and FEV1 percent predicted values of at least 0.70

Exclusion criteria

Exclusion Criteria:

  • Pregnant or trying to become pregnant (if capable of becoming pregnant- a urine pregnancy test will be provided onsite and a negative result must be obtained prior to the first testing session)
  • Smoking of any substance in the last six months
  • Diagnosed or suspected pulmonary disease (e.g., asthma, )
  • History of chronic cough
  • History of head or neck cancer
  • History of neurological disease (e.g., cerebrovascular accident)
  • History of dysphagia (swallowing difficulty)
  • Current complaint of a voice problem
  • Current upper respiratory infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Active comparator
    Dosimeter-Controlled Cough Reflex Sensitivity Testing

    Participants will undergo cough reflex sensitivity testing using a dosimeter-controlled nebulizer system (Cosmed QuarkSpiro) to deliver aerosolized citric acid.

    Device: Cosmed QuarkSpiro Dosimeter-Controlled Nebulizer

  • Experimental
    Handheld Nebulizer Cough Reflex Sensitivity Testing

    Participants will undergo cough reflex sensitivity testing using a handheld nebulizer (DeVilbiss 45) to deliver aerosolized citric acid.

    Device: DeVilbiss 45 Handheld Nebulizer

Interventions

  • DeviceCosmed QuarkSpiro Dosimeter-Controlled Nebulizer

    Laboratory spirometry system equipped with a dosimeter-controlled nebulizer used to deliver standardized aerosolized citric acid during cough challenge testing.

  • DeviceDeVilbiss 45 Handheld Nebulizer

    Commercial handheld nebulizer used to deliver aerosolized citric acid during cough challenge testing.

06

What researchers measure

Primary outcomes

  1. Test-retest reliability of the concentration of citric acid that elicits two or more coughs (C2)

    The test-retest reliability (Intraclass correlation coefficient) of the citric acid concentration required to elicit two coughs during cough challenge testing will be evaluated and compared for each testing method.

    Time frame: Cough sensitivity testing to determine cough thresholds (C2) will be performed at each of four weekly study visits, with visits occurring every 7 days across a 4-week study period.

  2. Test-retest reliability of the concentration of citric acid that elicits five or more coughs (C5)

    The test-retest reliability (Intraclass correlation coefficient) of the citric acid concentration required to elicit five coughs during cough challenge testing will be evaluated and compared for each testing method.

    Time frame: Cough sensitivity testing to determine cough thresholds (C5) will be performed at each of four weekly study visits, with visits occurring every 7 days across a 4-week study period.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data supporting the results reported in publications will be available upon reasonable request to the Principle Investigator following publication of study findings.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD and supporting information will be available as soon as one month after data are published and available for up to three years after publication.

Access criteria: Data will be shared with qualified investigators who provide a methodologically sound proposal and documentation of appropriate institutional approvals, where required. Data will be shared in a de-identified format consistent with institutional policies and applicable privacy protections. Due to the small sample size, additional safeguards may be implemented to prevent potential participant re-identification.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.

Of 79 non-industry interventional studies with no phase under Cough, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 6 months is below that.

Counting every sponsor, half of 87 studies reached it within 15 months; a quarter within 6 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Apr 15, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 28, 2027
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07531901
Lead sponsor
University of Montana
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Jul 15, 2026
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jul 20, 2026

Study contacts

Jane E Salois, PhD
Contact
jane.salois@umontana.edu
406-243-2138
Laurie J Slovarp, PhD
Contact
laurie.slovarp@umontana.edu
406-243-2107

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion